| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4004618 | American Journal of Ophthalmology | 2009 | 8 Pages |
Abstract
Both the anterior juxtascleral depot of a drug and anecortave acetate may be promising candidates for IOP reduction in eyes with OAG. Additional studies are required to establish better their efficacy and safety, optimal dosing frequency, mechanism of action, and potential additivity to other IOP-lowering therapies.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Alan L. Robin, Abbot F. Clark, David W. Covert, Scott Krueger, Michael V.W. Bergamini, Theresa A. Landry, Jaime E. Jr, Sally A. Scheib, Tony Realini, Joseph M. Defaller, Gerald D. Cagle,